Clinical testing of omnipaque and amipaque in external carotid and vertebral angiography: randomized double-blind crossover study.
Omnipaque, 300 mg l/ml, was compared with Amipaque, 300 mg l/ml, for cerebral angiography. Twelve patients were included in a randomized, double-blind, crossover study. Twenty comparisons were made in the external carotid and 21 in the vertebral artery, Both contrast media caused no or minor changes in blood pressure and heart rate. Good to excellent radiographic visualization of the cerebral arteries was obtained with both agents. The frequency of subjective reactions was almost equal, but the intensity of the reactions was less with Amipaque. No severe reactions were observed. Omnipaque is a more practical nonionic contrast medium than Amipaque because it is delivered in ready-to-use solutions.
D000328:Adult; D000368:Aged; D002342:Carotid Artery, External; D002533:Cerebral Angiography; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D007463:Iodobenzoates / Q000008:administration & dosage*; D007472:Iohexol; D008297:Male; D008793:Metrizamide / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D014711:Vertebral Artery
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008793:Metrizamide